--- title: "China NT Pharma Discloses Governance Dispute Behind Director’s Resignation" type: "News" locale: "en" url: "https://longbridge.com/en/news/286976652.md" description: "China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices." datetime: "2026-05-19T22:58:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286976652.md) - [en](https://longbridge.com/en/news/286976652.md) - [zh-HK](https://longbridge.com/zh-HK/news/286976652.md) --- # China NT Pharma Discloses Governance Dispute Behind Director’s Resignation ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks China NT Pharma Group Co., Ltd. ( (HK:1011) ) just unveiled an update. China NT Pharma Group Co., Ltd. disclosed further details following the earlier resignation of independent non-executive director Mr. Ng Ming Kwan. The board said it received a written statement from Mr. Ng on 18 May 2026, after his resignation and the initial announcement, outlining disagreements that he believes should be drawn to shareholders’ attention. Mr. Ng argued he was not properly informed of, or involved in, certain historic and recent transactions that may have constituted notifiable or connected transactions under Hong Kong’s Listing Rules. He said he only became aware of these matters and related compliance issues shortly before the company published its announcement on past transactions on 8 May 2026. In his statement, Mr. Ng contended that the past transactions announcement misrepresented his awareness and involvement, and that he should not be held responsible for those matters. He also raised concerns over the accuracy and adequacy of disclosure, particularly regarding the identification of non-compliances, attribution of responsibility and the description of remedial measures. Mr. Ng further claimed he was asked to approve the past transactions announcement without being given sufficient information or documentation, and that his requests for more details were not addressed before publication. He cited weaknesses in internal governance, compliance processes and board-level information flow, stating that these conditions prevented him from satisfactorily discharging his duties and led to his resignation. The board stressed that Mr. Ng’s written statement reflects his position only and that it does not necessarily agree with his views. The company said it is reviewing the issues he raised and will provide additional information or clarification where appropriate, signaling potential ongoing governance and compliance scrutiny that may be closely watched by investors and regulators. **More about China NT Pharma Group Co., Ltd.** China NT Pharma Group Co., Ltd. is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 1011. The group is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical listed-company structure subject to Hong Kong Listing Rules and corporate governance requirements. **Average Trading Volume:** 313,467 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$578.9M Find detailed analytics on 1011 stock on TipRanks’ Stock Analysis page. ### Related Stocks - [01011.HK](https://longbridge.com/en/quote/01011.HK.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) ## Related News & Research - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen](https://longbridge.com/en/news/286577625.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)